|
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
|
|
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
|
|
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
|
|
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications
|
|
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia
|
|
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
|
|
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias
|
|
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells
|
|
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
|
|
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|
|
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
|
|
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies
|
